Press Releases

– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines 1 ,2 ,3 – LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and safety results in patients with spasticity associated with multiple sclerosis CARLSBAD, Calif.,

– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and

– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year – – Total Epidiolex ®  net product sales of $144.1 million for the fourth quarter and $510.5 million for the full year – – Previously announced agreement to be acquired by Jazz Pharmaceuticals; transaction

Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster Enhanced product diversification of combined company expected to provide accelerated double-digit revenue growth

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year - - Total Epidiolex ®  preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year – -

LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive

EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized CARLSBAD, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid

LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham

- Meeting Highlights Include New Long-Term D ata in Tuberous Sclerosis Comple x - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S.